Kidney transplant from hepatitis C viremic donors into aviremic recipients and risk for post-transplant BK and cytomegalovirus infection.

Autor: Daloul R; Division of Nephrology, Kidney and Pancreas Transplant Program, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA., Schnelle K; Department of Internal Medicine, Division of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Von Stein L; Department of Internal Medicine, Division of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Logan A; Department of Surgery, Division of Transplantation, The Ohio State University College of Medicine, Columbus, Ohio, USA., Singh P; Department of Internal Medicine, Division of Nephrology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Yenebere P; Department of Internal Medicine, Division of Nephrology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Pesavento T; Department of Internal Medicine, Division of Nephrology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Washburn K; Department of Surgery, Division of Transplantation, The Ohio State University College of Medicine, Columbus, Ohio, USA.
Jazyk: angličtina
Zdroj: Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2022 Aug; Vol. 24 (4), pp. e13887. Date of Electronic Publication: 2022 Jul 13.
DOI: 10.1111/tid.13887
Abstrakt: Background: kidney transplantation from Hepatitis C virus (HCV) viremic donors to uninfected recipients is associated with excellent short-term outcomes. However, HCV viremia might be associated with an increased risk for post-transplant viral complications.
Methods: We designed a retrospective study of HCV-negative kidney-only transplant recipients between 2018 and 2020. Recipients were grouped into group 1; HCV-negative donors, and group 2; HCV-viremic donors. Patients were matched 1:1 using propensity score. The primary objectives were to compare the incidence of cytomegalovirus (CMV) viremia ≥ 200 ml/IU, and BK viremia ≥1000 copies/ml between the groups. Secondary outcomes included group comparison of CMV disease, BK viremia ≥10 000 copies/ml, and 1-year patient and allograft survival.
Results: The study included 634 patients in group 1, and 71 patients in group 2. Sixty-five pairs of patients were matched. Incidence of CMV viremia (33.3% vs. 40.0%, p = .4675), and BK viremia (15.9% vs. 27.7%, p = .1353) did not differ significantly between groups in the matched cohort. Incidence of CMV disease (81.0% vs. 76.9%, p = 1.000), and BK viremia ≥10 000 copies/ml (9.5% vs. 16.9%, p = .2987) were comparable between groups. There was no difference in the 1-year patient or allograft survival between groups.
Conclusion: kidney transplant from HCV-viremic donors is not associated with increased risk for BK or CMV viremia.
(© 2022 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje